We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Shailender Bhatia

Shailender Bhatia MD

Department of Medicine, University of Washington, Seattle, Washington

Dr. Shailender Bhatia is an Associate Professor in the Medical Oncology division at the University of Washington (UW)/Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA. He also serves as the Clinical and Research Director of the Melanoma-Renal program at the UW/FHCRC. He received his MBBS (equivalent to MD) degree at the prestigious All India Institute of Medical Sciences (AIIMS) in New Delhi, INDIA and completed his Internal Medicine Internship and Residency at the University of Connecticut Health Center, Farmington, CT. He completed his fellowship in Hematology/Oncology at the UW/FHCRC, Seattle, WA.

Dr. Bhatia’s research efforts are mostly focused on improving outcomes in skin cancers (especially Melanoma and Merkel cell carcinoma). He has led numerous clinical trials of all phases investigating novel immunotherapy approaches in skin cancers. He has a special interest in intra-tumoral and targeted immunotherapy trials that deliver the drugs into the tumor microenvironment to spare systemic toxicity. 

Disclosures

Dr. Bhatia reports the following:
  • Advisory board/Consultant (with honorarium): Genentech, Bristol-Myers Squibb, EMD-Serono, Sanofi-Genzyme, Castle Biosciences, Exicure.
  • Speaker Bureau: None
  • Research grants (to institution): Bristol-Myers Squibb, EMD-Serono, Merck, Novartis, Immune Design, Incyte, Oncosec, Nantkwest, Exicure, Nektar, Amphivena, Checkmate, Xencor, 4SC.
  • Stock/Equity: Moderna